<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060629</url>
  </required_header>
  <id_info>
    <org_study_id>CR108263</org_study_id>
    <secondary_id>VAC89220HPX2008</secondary_id>
    <secondary_id>HVTN 705</secondary_id>
    <secondary_id>HVTN 705/VAC89220HPX2008</secondary_id>
    <nct_id>NCT03060629</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the preventive vaccine efficacy (VE), safety
      and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and
      aluminum-phosphate adjuvanted Clade C gp140 for the prevention of Human Immuno Virus (HIV)
      infection in HIV-seronegative women residing in sub-Saharan Africa from confirmed HIV-1
      infections diagnosed between the Month 7 and Month 24 visits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor will be also blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Efficacy (VE) as Derived From Confirmed HIV-1 Infections Diagnosed Between the Month 7 and Month 24 Visits</measure>
    <time_frame>From Month 7 to Month 24</time_frame>
    <description>VE (7-24) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 7 and Month 24 after enrollment in the Per-Protocol (PP) population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Reactogenicity Sign or Symptom</measure>
    <time_frame>3 days after each vaccination</time_frame>
    <description>Each participant's reactogenicity will be counted once under the maximum severity for each injection visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>30 Days after each vaccination (Approximately up to 42 Months)</time_frame>
    <description>Adverse events by body system, severity, and assessed relationship to study products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between Enrollment and the Month 24 Visit</measure>
    <time_frame>From Baseline to 24 Months</time_frame>
    <description>VE (0-24) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 0 and Month 24 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between Enrollment and the Month 36 Visit</measure>
    <time_frame>Baseline up to 36 Months</time_frame>
    <description>VE (0-36) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 0 and Month 36 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between the Month 12 and the Month 24 Visits</measure>
    <time_frame>From Month 12 to Month 24</time_frame>
    <description>VE (12-24) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 12 and Month 24 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between the Month 12 and the Month 36 Visits</measure>
    <time_frame>From Month 12 to Month 36</time_frame>
    <description>VE (12-36) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 12 and Month 36 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of the Vaccine Regimen</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>Immunogenicity of the vaccine regimen, assessed by Vaccine-specific antibody and T cell responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity and Immune Response Biomarkers as Correlates of Risk of Subsequent HIV Acquisition</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>Immunogenicity and Immune Response are assessed by BiomarkersVaccine-specific antibody and T cell responses correlated with vaccine efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy Assessed by Various Baseline and Demographic Characteristics</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>The vaccine efficacy assessed by various baseline and demographic characteristics diagnosed by HIV-1 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic Characteristics of Viral Sequences From HIV-1 Infected Participants at HIV-1 Diagnosis, Such as Signature Site Mutations</measure>
    <time_frame>Baseline up to 36 Months</time_frame>
    <description>The genotypic characteristics of viral sequences from HIV-1-infected participants at HIV-1 diagnosis assessed by signature site mutations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Genomic Sequences of Viral Isolates From HIV-1 Infected Vaccine and Placebo Recipients and Assessment by Sieve Analysis Methods of Whether There is Evidence of Vaccine-Induced Immune Pressure on the Viral Sequences</measure>
    <time_frame>Baseline up to 36 Months</time_frame>
    <description>Viral sequences from HIV-1-infected participants at HIV-1 diagnosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.Mos4.HIV</intervention_name>
    <description>Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clade C gp140</intervention_name>
    <description>Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sexually active, defined as having had sexual intercourse with a male partner at least
             twice in the past 30 days prior to screening, and is considered by the site staff to
             be at risk for Human Immunodeficiency Virus (HIV) infection

          -  Access to a participating HIV Vaccine Trials Network (HVTN) Clinical Research Sites
             (CRS) and willingness to be followed for the planned duration of the study

          -  Willingness to discuss HIV infection risks and willing to receive HIV risk reduction
             counseling and appropriate referrals to minimize HIV acquisition, as applicable

          -  Negative beta human chorionic gonadotropin (beta-HCG) pregnancy test performed prior
             to vaccination on the day of initial vaccination. Persons who are NOT of reproductive
             potential due to having undergone total hysterectomy or bilateral oophorectomy
             (verified by medical records), are not required to undergo pregnancy testing

          -  Participants must also agree not to seek pregnancy through alternative methods, such
             as artificial insemination or in vitro fertilization until 3 months after the last
             vaccination

        Exclusion Criteria:

          -  Investigational research agents received within 30 days before first vaccination

          -  HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received
             control/placebo in an HIV vaccine trial, the HVTN 705/HPX2008 (Protocol Safety Review
             Team) PSRT will determine eligibility on a case-by-case basis

          -  Live attenuated vaccines other than influenza vaccine received within 30 days before
             first vaccination or scheduled within 14 days after injection (example: measles,
             mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever)

          -  Influenza vaccine or any vaccines that are not live attenuated vaccines and were
             received within 14 days prior to first vaccination (eg, tetanus, pneumococcal,
             Hepatitis A or B)

          -  Immunosuppressive medications received within 6 months before first vaccination
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC Lilongwe Project</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polana Cani√ßo Health Research and Training Center (CISPOC)</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Josha Research</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emavundleni Research Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7750</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cape Town IDM/CIDRI Research Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7784</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masiphumelele Research Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7975</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ndlovu Elandsdoorn Site</name>
      <address>
        <city>Dennilton</city>
        <zip>0485</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Diepkloof</city>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Klerksdorp Clinical Research Centre</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo Research Centre</name>
      <address>
        <city>Kwazulu-Natal</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South African Medical Research Council Chatsworth Clinical Research Site</name>
      <address>
        <city>Kwazulu-Natal</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for the AIDS Programme of Research in South Africa</name>
      <address>
        <city>Kwazulu-Natal</city>
        <zip>4110</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South African Medical Research Council Tongaat Clinical Research Site</name>
      <address>
        <city>Kwazulu-Natal</city>
        <zip>4399</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanza Clinical Research Centre : Mamelodi</name>
      <address>
        <city>Mamelodi East</city>
        <zip>122</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HIV Vaccine Research Unit, Mthatha</name>
      <address>
        <city>Mthatha</city>
        <zip>5099</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MeCRU Clinical Research Unit</name>
      <address>
        <city>Pretoria</city>
        <zip>204</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Rustenburg Clinical Research Site</name>
      <address>
        <city>Rustenburg</city>
        <zip>300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Soshanguve</city>
        <zip>152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU), Kliptown</name>
      <address>
        <city>Soweto</city>
        <zip>1809</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa Clinical Research Centre</name>
      <address>
        <city>Tembisa</city>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambia Emory HIV Research Project (ZEHRP)</name>
      <address>
        <city>Lusaka</city>
        <zip>P/BagE891</zip>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia (CIDRZ)</name>
      <address>
        <city>Matero, Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zambia Emory HIV Research Project (ZEHRP)</name>
      <address>
        <city>Ndola</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Mary's Clinic</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe-UCSF</name>
      <address>
        <city>Harare - Seke South</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>Mozambique</country>
    <country>South Africa</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108263</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

